Details for Patent: 11,680,069
✉ Email this page to a colleague
Which drugs does patent 11,680,069 protect, and when does it expire?
Patent 11,680,069 protects RINVOQ LQ and RINVOQ and is included in two NDAs.
This patent has forty-four patent family members in thirteen countries.
Drugs Protected by US Patent 11,680,069
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | 11,680,069 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | No | 11,680,069 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-002 | Jan 14, 2022 | RX | Yes | No | 11,680,069 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-003 | Mar 16, 2022 | RX | Yes | Yes | 11,680,069 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,680,069
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016340167 | ⤷ Subscribe | |||
| Australia | 2020359635 | ⤷ Subscribe | |||
| Australia | 2021236570 | ⤷ Subscribe | |||
| Australia | 2023251492 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
